UC Davis School of Medicine professors discuss the Pfizer-BioNTech vaccine – The Aggie

Microbiology and immunology professors explain the COVID-19 vaccine and what sets it apart from past vaccines

On Dec. 11, 2020, the Pfizer-BioNTech vaccine was approved for use by the Food and Drug Administration (FDA) after a series of experimental trials since mid-March. The Moderna vaccine also received emergency authorization from the FDA on Dec. 18, 2020. Barbara Shacklett, a professor at the UC Davis School of Medicine whose research focuses on cell-mediated immune responses to HIV, noted that although the vaccine hasnt taken long to be approved, the experimental process wasnt carried out hastily.

Even though the vaccine has become available in record time, it nevertheless went through extensive testing in clinical trials to determine that it was both safe and effective, Shacklett said via email. The process was accelerated in this case because of the urgency of the situation, but that doesnt mean important steps were skipped or overlooked.

Dr. Stefan Rothenburg, an associate professor in the School of Medicines department of medical microbiology and immunology, emphasized that no serious symptoms have been linked to the vaccine.

I think the short term safety profiles are very encouraging, Rothenburg said. There have been very few serious side effectsyou cannot really call it side effectsbut very few instances where some of the participants in the trials had some disease. But it has been concluded by the expert panel that this had nothing to do with the vaccine.

According to Rothenburg, some of the trial participants who experienced symptoms were part of a placebo group.

In the placebo groups they had some cases where people developed some health issues, Rothenburg said. And this is just kind of normal. If you have a large number of participants, some people, in a random fashion, will always develop some health issues.

Vaccines use a form of antigen that the immune system recognizes and responds to. According to Shacklett, vaccines can be made up of weakened strains of a virus, lifeless virus particles or a small piece of the virus particleusually a protein. The Pfizer-BioNTech vaccine employs the last method; however, the genetic information called messenger RNA (mRNA) is used instead of a protein. The Pfizer-BioNTech vaccine is the first mRNA vaccine to be approved for general use.

The vaccine contains a very small piece of the SARS-CoV2 virus RNA, Shacklett said. Once its in a persons body, this RNA serves as a template so that the persons cells can produce a single, strongly immunogenic protein from the virus, the spike protein. Importantly, this small piece of RNA doesnt contain nearly enough information to produce the whole virus.

Shacklett stated that after the body uses the mRNA, its discarded.

Once the vaccine material is taken up by our bodys cells, it is read by the cellular machinery that makes proteins, but afterwards it is completely broken down and lost, Shacklett said. The mRNA does not become stably integrated into our cells; instead, after it is used as a template, its destroyed by enzymes inside our cells.

Rothenburg mentioned that the majority of Americans are leaning toward becoming vaccinated.

Right now it seems that at least 80% of the population in the U.S. have a positive view of the [COVID-19] vaccines, Rothenburg said. So I think about 40% would take it right away. Another 40% want to wait a little bit, but its generally a positive and this is definitely encouraging.

According to Rothenburg, the virus wont be able to be transmitted if a certain threshold is reached in the number of vaccinated individuals.

If we get a vaccination coverage of between 70 and 80%, we are at the stage where the virus would have problems to get transmitted, basically because people are more immune, Rothenburg said.

Dr. Jose Torres, a professor in the department of medical microbiology and immunology whose research focuses include viral immunology, stated that the vaccine will likely offer immunity for months.

A few months of protection (three to six) is a reasonable expectation until we gather results from a large number of vaccinees, Torres stated in an email. The real long-term efficacy can only be determined a few years after widespread vaccine introduction.

Both the Pfizer and Moderna vaccines have proven to have a more than 90% success rate.

Many scientists that are experts in this field are very surprised with the

exceptionally high early protection levels reported by the companies that developed the final

versions of these new types of vaccines, Torres said. Time will tell if this becomes a safe and reliable technology for inducing long-term protection and memory.Written by: Lyra Farrell features@theaggie.org

Read the original post:
UC Davis School of Medicine professors discuss the Pfizer-BioNTech vaccine - The Aggie

Delaying Second Dose of COVID-19 Vaccines ‘The Right Thing to Do’ – Medscape

The decision to delay second doses of the COVID-19 vaccines to increase uptake of initial immunisation was the right thing to do, experts said.

Prof Andrew Goddard, president of the RCP, said he had "thought long and hard" about the decision but had concluded "it was the right thing to do".Eleanor Riley, professor of immunology and infectious disease at the University of Edinburgh, admitted she had been sceptical initially about the decision but that "the more I thought about it, the more it made perfect sense".

Prof Eleanor Riley/RCP

On December 31, the Joint Committee on Vaccination and Immunisation decided that vaccinating a greater number of people with a single dose would prevent more deaths and hospitalisations than vaccinating a smaller number of people with two doses. It said that efficacy for the Pfizer/BioNTech vaccine against symptomatic COVID-19 following an initial dose was 89% from day 14 after the vaccination was administered.

It also found that the level of protection after a single dose of the AstraZeneca/Oxford vaccine was 73% after 22 days following the first dose.

The JCVI recommended a gap of up to 12 weeks between the first and second doses of both vaccines.

The move was controversial among some scientists and clinicians who pointed out that the wider spacing regimen went against the methods used in clinical trials where doses were administered at 3 or 4 week intervals.

Prof Riley told the RCP's 2021 conference that in the case of the AstraZeneca/Oxford vaccine, data showed that "the immunological response with a second dose at 12 weeks is certainly no worse and actually looks really a little bit better than giving an earlier second dose".

She said the results built on research over the last few years on vaccination dosing schedules that suggested "a delayed second dose is frequently beneficial".

Some older vaccination dosing schedules "may have been unnecessarily quick", she added.

However, Prof Riley cautioned that longer intervals between vaccine doses could drive down patient compliance.

"Life gets in the way, people move house, people change jobs, people get other diseases, things happen at home that means people don't get the letter inviting them for their second dose, or they are just unable to return.

"And the longer you leave it, the bigger the risk is of that."

Read more:
Delaying Second Dose of COVID-19 Vaccines 'The Right Thing to Do' - Medscape

Impact of COVID-19 on Immunology Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Pfizer Inc., Amgen Inc., Merck Sharp &…

Immunology Market research report is the new statistical data source added by A2Z Market Research.

Immunology Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Immunology Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=336498

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Pfizer Inc., Amgen Inc., Merck Sharp & Dohme Corp., Astellas, Novartis AG, Other Prominent Players, ALLERGAN, F. Hoffmann-La Roche Ltd, Janssen Global Services, LLC (Johnson & Johnson), UCB SA, AbbVie Inc., Bristol-Myers Squibb Company

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Immunology market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Immunology markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=336498

Global Immunology Market Segmentation:

Market Segmentation by Type:

Rheumatoid ArthritisPsoriatic ArthritisPlaque PsoriasisAnkylosing SpondylitisInflammatory Bowel DiseaseProphylaxis of Organ Rejection

Market Segmentation by Application:

Hospital PharmaciesRetail PharmaciesOnline Pharmacies

Regions Covered in the Global Immunology Market Report 2020:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The report provides insights on the following pointers:

Table of Contents

Global Immunology Market Research Report 2020 2026

Chapter 1 Immunology Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Immunology Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=336498

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

https://farmingsector.co.uk/

See more here:
Impact of COVID-19 on Immunology Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Pfizer Inc., Amgen Inc., Merck Sharp &...

Severe sepsis predicted by common protein – Newswise

Newswise A sugar-binding protein could fuel terrible inflammation and worsen sepsis, a disease that kills more than 270,000 people every year in the US alone, reports a team of researchers led by UConn Health in the 4 January issue ofNature Immunology.

Sepsis is caused mostly by bacterial infections. The immune system runs out of controls and triggers a cytokine storm, a condition in which inflammation-causing proteins flood the blood. Organs may break down, and death often follows.

Other diseases can also cause cytokine storms; medical historians believe cytokine storms were behind the lethality of the 1918-1919 flu epidemic, as well as the Black Death. Cytokine storms are also observed in patients with severe COVID-19 and believed to be involved in death in COVID-19.

A main trigger for the cytokine storms during sepsis is the overreaction of the body when it detects an infection inside the cells. When a cell detects bacteria or pieces of bacteria inside itself, it immediately activates enzymes that in turn activate a protein that pokes holes on the cell membrane from within, eventually causing the cell to burst open and spill cytokines into the bloodstream. Cytokines are alarm signals, calling in the immune system to fight the bacteria. Cytokines also make other cells more likely to burst open and sound the alarm. Usually, the system damps itself after a while and calms down, but in sepsis it spins out of control, causing more and more cells to burst and die and release even more cytokines into the bloodstream.

When cells burst open, they release not only cytokines, but also other danger molecules called alarmins that alarm the body of an infection or injury and can amplify the ongoing cytokine storm.

UConn Health immunologist Vijay Rathinam wanted to know which alarmins were released when a cell detected a specific kind of bacterial molecule called lipopolysaccharide inside itself. Dr. Ashley Russo, then a graduate student in the Rathinam lab, catalogued--in collaboration with immunologists Tony Vella and Antoine Menoret at UConn Health--proteins released by these cells when they detected lipopolysaccharide.

And they found something exciting. Galectin-1, a protein that binds sugars and sugar-coated proteins, seemed to be emanating from the cells. Interestingly, they found that galectin-1 is small enough to be slipping out of the holes poked in the cells' membrane, even before the cells burst open.

Once they noticed that, they began to look at the role galectin-1 played in sepsis. They found that galectin-1 seemed to be suppressing a brake on inflammation, causing the cytokine storm to ramp up. They also found that mice lacking galectin-1 had less inflammation, less organ damage, and survived longer than normal mice did during sepsis resulting from a bacterial infection and lipopolysaccharide.

To find out if galectin-1 is released during sepsis in human patients, the team collaborated with the Jena University Hospital's Drs. Deshmukh, Bauer, and Sponholz and found that sepsis patients had higher levels of galectin-1 than other non-sepsis patients in critical care and healthy people.

The team is considering whether galectin-1 might be a good drug target to help dampen cytokine storms during sepsis, as well as a useful marker doctors could use to identify critical ill patients at risk.

###

This study was made possible by key additional collaborations with the laboratories of Dr. Gabriel Rabinovich of the Laboratorio de Inmunopatologa, Instituto de Biologa y Medicina Experimental, Consejo Nacional de Investigaciones Cientficas y Tcnicas in Buenos Aires, Argentina, Drs. Beiyan Zhou, Sivapriya Kailasan Vanaja, and Jianbin Ruan of UConn Health, and Dr. Greg Hudalla of University of Florida.

This project was funded by grants from the National Institutes of Health to Dr. Rathinam.

Continue reading here:
Severe sepsis predicted by common protein - Newswise

Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials – BioSpace

CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells for treating cancers, launched today with over $50 million in financing to initiate multiple clinical trials in 2021. The Company combines advanced gene and cell engineering capabilities with substantial biologics knowledge to elucidate and redirect the power of myeloid cells to treat cancers, particularly solid tumors and those that are poorly served by existing therapies. Myeloid has advanced its lead development candidates through preclinical studies, implemented its manufacturing platform and plans to dose patients in the first half of this year.

The Company's scientific founders include Ronald Vale, Ph.D., a world-renowned biochemist and cell biologist, and executive director of the Howard Hughes Medical Institute (HHMI) Janelia Research campus; and hematologist, oncologist and Pulitzer-Prize winning author Siddhartha Mukherjee, M.D., D.Phil. Newpath Partners led the financing round with participation from 8VC, Hatteras Venture Partners and Alexandria Venture Investments.

With this funding, Myeloid will initiate clinical trials for the Company's programs, which target T cell lymphoma, glioblastoma and other solid tumors. The team will also continue to design and advance a broad pipeline of targeted myeloid cell therapies, including primed myeloid cells, myeloid multi-specific engagers and other development candidates created with Myeloid's novel mRNA delivery technologies. The Company expects to enter the clinic with its two lead programs in glioblastoma and T cell lymphoma in 2021.

"I believe Myeloid is best positioned to leverage the unique power of myeloid cells to help patients fighting cancers that until now, have been very difficult to treat," said Dr. Mukherjee. "Despite the promise of current cell therapies, many challenges remain when it comes to targeting specific types of cancers, including solid tumors, and in efficiently manufacturing treatments. I'm thrilled to help develop Myeloid's transformative treatment modality, which has the potential to overcome many of these challenges."

"Myeloid cells play a critical role in orchestrating the body's immune responses, including by directly killing cells, bacteria and viruses through a number of disease-fighting mechanisms," said Michael Dee Gunn, M.D., Professor of Medicine and Immunology at Duke University, and a pioneer in the research of molecular mechanisms of innate immunity and inflammation and a member of Myeloid's Scientific Advisory Board. "This novel class of cell therapies has strong potential to benefit patients with the highest unmet medical needs."

ATAKTM Cell Platform

The Company's ATAK platform was inspired by Drs. Vale and Mukherjee, who envisioned the disease-fighting power of myeloid cells versatile cells with effector functions capable of targeting and eliminating cancerous cells, along with other harmful cells in the body. Within the oncolytic setting, the ATAK platform is being applied to harness the innate abilities of myeloid cells, to specifically recognize and engulf cancer cells, to produce anti-tumor agents, promote anti-tumor adaptive immunity, alter the tumor microenvironment and ultimately to kill cancer. In addition to reprogramming monocytes to target difficult-to-treat cancers, the platform offers Myeloid and its partners many additional advantages, including novel mRNA-based protein and gene delivery, a library of intermixed cell receptors, and chimeric antigen receptors (CARs) that may be applied to enhance treatment effects or to engineer novel tri- and bi-specific cell engagers.

Myeloid is currently focused on advancing two categories of novel ATAK therapies: ATAK CAR monocytes and ATAK primed monocytes. ATAK CAR monocytes are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. ATAK primed monocytes function like cell vaccines, programmed to trigger T cells to kill cancer cells.

Manufacturing candidates from the ATAK platform benefit from speed and scalability in manufacturing process development. The Myeloid team can scale manufacturing rapidly, from product concept to clinical use. In addition, current products derived from the ATAK platform have a single-day cell manufacturing process. Given the observed strengths of the manufacturing process, Myeloid reasonably envisions same-day ATAK platform treatment, especially relevant upon clinical presentation of aggressive tumors. The Company is also in the process of developing "off the shelf" approaches in order to advance the full range of clinical delivery options.

Myeloid Leadership and Scientific Advisory Board

As co-founder and Chief Executive Officer of Myeloid, Daniel Getts, Ph.D., MBA, oversees the Company's portfolio and growth strategies. Dr. Getts is a repeat biotech entrepreneur, having led research at TCR2 through its IPO and the development of the first cell therapy to show clinical responses in ovarian cancer. Before that, he co-founded Cour Pharmaceuticals Development Company.

The Company's Scientific Advisory Board includes world-renowned scientists whose expertise span oncology, immunology, cell therapy, synthetic biology and genetic engineering:

"Our mission is to apply our energy and significant research capabilities to design and develop truly transformative treatments," said Dr. Getts. "We built Myeloid's ATAKTM platform to overcome many limitations of existing cell therapies, in part by embracing the natural tendencies of monocytes to penetrate solid tumors and catalyze immune reactions. By harnessing the power of monocytes, which are the cells that comprise the largest population of immune cells in the tumor microenvironment, we are working to bring new therapies to patients. We have also designed and successfully implemented an efficient, flexible manufacturing process that sets a new threshold for cell therapies. We are very pleased to have the support of this strong group of investors, who enable us to further develop the ATAK platform, to advance multiple solid tumor programs into the clinic, and to bring forward new transformative programs as we broaden Myeloid's pipeline."

"Myeloid cells are the body's front-line-disease-fighting tools, and they are critical in the orchestration of adaptive immune responses. These myeloid cells are overrepresented in solid cancers and I have been fascinated with their therapeutic potential since researching them during my medical training," said Thomas Cahill, M.D., Ph.D., Myeloid co-founder and Managing Partner of Newpath Partners. "Most other cell therapies focus on reprogramming the adaptive immune system and they have truly improved patient outcomes, especially with respect to liquid tumors. To expand on this promise, the next logical step was to empower the cells at the front lines of solid tumors. By engineering myeloid cells, the Company is developing an extremely versatile and potent class of new therapeutic agents. I look forward to continuing to support this team through their first wave of clinical trials and beyond."

About Myeloid Therapeutics

Myeloid Therapeutics is an immunology company focused on combining biology insights with cutting-edge technologies to harness myeloid cells and eradicate cancer and other diseases. With broad clinical applications possible, the Company is presently advancing its cell therapy product candidates, derived from its ATAKTM platform technology, with initial applications in T cell lymphoma and a primed monocyte approach to treating glioblastoma. The ATAK platform is scalable to multiple treatment modalities and to other disease areas in collaboration. Myeloid expects to enter the clinic with its two lead programs in the first half of 2021. For more information, visit https://www.myeloidtx.com/.

Media Contact:Sarah SuttonGlover Park Groupssutton@gpg.com202-337-0808

View original content to download multimedia:http://www.prnewswire.com/news-releases/myeloid-therapeutics-launches-with-over-50-million-in-financing-and-two-clinical-trials-301201589.html

SOURCE Myeloid Therapeutics, Inc.

Go here to see the original:
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials - BioSpace

The legal position of international surrogacy in England and Italy and the recognition of foreign parental orders – Lexology

In this blog, Connie Atkinson, Partner at Kingsley Napley, and Veronica Dindo, Solicitor at LawLab Studio Legale, look at the legal position in England & Wales and Italy and the recognition of foreign orders relating to the birth of children born following a surrogacy arrangement abroad.

Surrogacy in England and Wales by Connie Atkinson

The majority of parents we advise who have had a child using a surrogate have an international connection. One or both of the parents may have been born, or now live, abroad and/or the surrogacy arrangement may have taken place abroad. One of the questions I am regularly asked by parents is whether the legal position in either the country in which the child is born or the country in which the parents live is recognised in England. My answer is always no. There is currently no international convention on the recognition of laws relating to surrogacy arrangements and the ability to draft such a convention is likely to be difficult as surrogacy is viewed and treated so differently across the globe. England and Wales does not recognise the legal position in other countries even where surrogacy is a mature and well regulated practice.

In England and Wales, if a child is born following a surrogacy arrangement either here or abroad, the surrogate will be the legal mother (whether or not she is genetically related to the child) and her husband, if she is married, will be the legal father. This is the case no matter what the position is in the country in which the child is born. If the surrogate is not married, the biological father of the child may be considered the legal father under English law but he will not necessarily have parental responsibility (PR) for the child.

In order to extinguish the surrogates and her husbands PR and legal parentage, intended parents must currently make an application to the English court for a parental order (PO), which will formally recognise the intended parents as the legal parents under English law. In the case of an unmarried surrogate where the intended father is genetically related to the child, a PO is still required to extinguish the surrogates legal parentage, to give the intended mother or second intended parent legal parentage and, in the case of children born abroad, to give both intended parents PR.

In order to be eligible to make a PO, parents must meet the criteria set out in section 54 (for two applicants) and section 54A (for one applicant) of the Human Fertilisation and Embryology Act 2008 (s54 criteria).

Surrogacy in Italy - Veronica Dindo

In Italy, surrogacy practices are explicitly prohibited. In fact, anyone who creates, organises or advertises surrogacy commits an offense of criminal relevance (Article 12 paragraph 6 of Law 40/2004).

However, since surrogacy is legitimate in other countries, Italian courts have been faced, in recent years, with claims concerning the recognition of foreign orders and birth certificates for children born abroad by means of a surrogate.

Since there is no international convention on the subject, the criteria to be followed in relation to the recognition of foreign orders and birth certificates relating to a child born through surrogacy are those set out generally by the Italian Private International law (Law 218/1995). One of the requirements to enable the recognition of a foreign order is the compliance with public order(art. 64 - 68 letter g Law 218/1995; art. 18 Decree 396/2000; art. 23 EU Reg. 2201/2003).

Case law has arisen in cases involving parents by way of surrogacy because the parents, who are declared as such on the foreign birth certificates and/or orders, have had their requests for the recognition and registration of their status as parents rejected by the Italian authority (Birth Register Office).

The reason for the rejections was because to recognise them as parents would supposedly conflict with the public order, as those foreign orders and certificates related to the use of a practice that is explicitly prohibited and criminally sanctioned by Italian law. Same sex parenthood in itself was also considered as another potential reason of conflict against public order in Italy.

Decisions given by first instance courts (to which the parents resorted to obtain their formal recognition as parents in Italy) were inconsistent, causing uncertainty and unequal treatment. At the same time, however, the decisions are the only source of guidance or regulation in respect of the effects of surrogacy with regard to the childrens status and the rights of all parties involved, as no guidelines are provided by the Law (all the Law currently stipulates is that surrogacy as a practice is prohibited).

Recently, cases involving surrogacy arrangements have finally reached the Supreme Court of Cassation.

Italy is a civil law system, so there is no principle of the binding precedent (whereby precedents set by the higher courts must be followed by the lower courts) and judges are subject only to the law (art. 101 Italian Constitution). However, the rulings given by the Supreme Court of Cassation, especially when sitting in Joint Sessions, are particularly authoritative.

This Court has a function of ensuring the correct interpretation of the law and so if lower courts decide to deviate from the principles stated in its judgments, they need to explain their reasons why (art. 374 co. 4 Italian civil procedure code).

Summary

The above quite different legal systems and processes by which parents can be legally recognised as their childrens parents highlights the difficulties with creating families across international borders. It is imperative that parents take legal advice at home, the country in which their child will be born and in any other country in which they have a significant connection before embarking on any surrogacy arrangement.

This blog was originally published in the November 2020 issue of Family Law Journal.

See original here:
The legal position of international surrogacy in England and Italy and the recognition of foreign parental orders - Lexology

CPS Energy Designated 2020 Customer Champion For 4th Consecutive Year And 6th Time Since 2014 – PRNewswire

SAN ANTONIO, Jan. 5, 2021 /PRNewswire/ --Escalent, a top human behavior and analytics firm, designated CPS Energy as a 2020 Customer Champion. CPS Energy ranked 1st in the U.S. Southern Region for 2020 as a combined (electric & natural gas) utility with a score of 749 (on a 1,000-point benchmark scale), an increase from 733 in 2019.These results are from the 2020 Cogent Syndicated Utility Trusted Brand & Customer Engagement: Residential study.

The study benchmarks and trends performance of 140 utilities on the Engaged Customer Relationship (ECR) index- a comprehensive customer relationship measurement used by utility management to assess customer engagement. This year's results reflect strengthened brand perceptions and increased product engagement.

"Engaging customers beyond simply satisfying service needs is now a utility reality to ensure future success. Scoring well on the ECR index is critical to growing company value and stakeholder support," said Chris Oberle, senior vice president at Escalent. "Utilities have confronted a very tough year by building customer support for their environmental, social, product and management efforts. Our 2020 Customer Champions are leading the pack on these ESG principles."

The 2020 Customer Champion designation marks the 4th consecutive year CPS Energy has been ranked #1 in the U.S. Southern Region for a combined utility. This is the 6th time the company has been recognized since 2014.

"CPS Energy is honored to be recognized by Escalent as a 2020 Customer Champion," said Chief Customer Engagement Officer, Rudy Garza. "Despite the challenges facing our entire community during this pandemic, our 3,100 employees, who are truly People First Champions, are working to ensure our community receives Reliable, Customer Affordable, Safe, Secure, Environmentally ResponsibleandResilientservice, and we are committed to continue to do so as we move into the next year." The study designates 42 national utilities as 2020 Customer Champions. These utilities performed above their peers to be given the 2020 Customer Champion designation.

Below is a table with all 2020 Customer Champions.

Cogent Syndicated 2020 Utility Customer Champions

AEP Ohio

Duquense Light

Pepco

Atmos Energy- South

Elizabethtown Gas

Piedmont Natural Gas

Avista

Idaho Power

PPL Electric Utilities

BGE

Intermountain Gas Company

PSE&G

Black Hills Energy- Midwest

Kentucky Utilities

RG&E

Cascade Natural Gas

MidAmerican Energy

Salt River Project

CenterPoint Energy- Midwest

Montana-Dakota Utlities

SDG&E

Columbia Gas- South

New Jersey Natural Gas

TECO Peoples Gas

Columbia Gas of Ohio

NIPSCO

Texas Gas Service

CPS Energy

NW Natural

Toledo Edison

Dayton Power & Light

Oklahoma Natural Gas

Washington Gas

Delmarva Power

OUC

Wisconsin Public Service

DTE Energy

PECO Energy

Xcel Energy- Midwest

Duke Energy Midwest

Peoples Gas

Xcel Energy- West

About CPS Energy Established in 1860, CPS Energy is the nation's largest public power, natural gas, and electric company, providing safe, reliable, and competitively-priced service to 860,934 electric and 358,495 natural gas customers in San Antonio and portions of seven adjoining counties. Our customers' combined energy bills rank among the lowest of the nation's 20 largest cities while generating $8 billion in revenue for the City of San Antonio for more than seven decades. As a trusted and strong community partner, we continuously focus on job creation, economic development and educational investment. True to our People First philosophy, we are powered by our skilled workforce, whose commitment to the community is demonstrated through our employees' volunteerism in giving back to our city and programs aimed at bringing value to our customers. CPS Energy is among the top public power wind energy buyers in the nation and number one in Texas for solar generation.

SOURCE CPS Energy

http://www.cpsenergy.com

The rest is here:
CPS Energy Designated 2020 Customer Champion For 4th Consecutive Year And 6th Time Since 2014 - PRNewswire

10 things we learned in 2020 about living the good life – KCTV Kansas City

What do you need for a meaningful life? Even as 2020 strained communities around the world, it offered some object lessons in living well.

In the widespread nostalgia for pre-pandemic gatherings and rituals, we saw just how much we depend on other people. When medical and other frontline workers risked their own health to support entire communities, the world watched the everyday impact of lives dedicated to service.

"There are so many things that we are going to learn from 2020," said Emiliana R. Simon-Thomas, science director of the University of California, Berkeley's Greater Good Science Center. "We've really had a coming to terms with how important our collective experiences are to health and well-being."

And even as they, like the rest of us, coped with an ongoing pandemic, researchers studying the science of well-being uncovered key insights into what makes life meaningful. The findings include the benefits of empathy, gratitude and cooperation, with ideas for increasing happiness in your own life or even in your country.

Simon-Thomas joined a team from the GGSC in December to select the 10 research findings from 2020 that shed light on the good life, and offer a positive road map for weathering the months and years to come. Here's what the team found.

Scientists already know that empathy is both a personality trait and a learned behavior. That's great, because it means that you can increase your empathy no matter your disposition. In turn, that can help forge stronger, more supportive relationships.

Being empathetic is about more than skill building, though. Your motivation to be empathetic matters, too, according to two studies published this year, one by Harvard University researchers and another from the University of Toronto.

Participants in the Harvard University study wrote letters describing the importance of empathy. Researchers speculated that it might boost the participants' motivation to be empathetic, and the strategy worked: A few months later, those same participants demonstrated more empathetic behavior.

Do it: Try the study on yourself. Write down the benefits of empathy in a journal entry, detailing why you think it's a valuable trait. It's a solid way to recharge your empathy after a difficult year.

Fair societies are happier, found a 2020 analysis of European Union countries using the EU Social Justice Index and reports of life satisfaction.

It's a strong correlation. Social justice was second only to social capital that's how researchers refer to our complex networks of relationships when it came to predicting each country's happiness.

Why? One of the study's authors, Isaac Prilleltensky, dean of education and human development at the Unviersity of Miami, has argued that a society's commitment to social justice shows individual citizens that they are valued by their broader community. That, in turn, leads to greater happiness.

Do it: Want a happier community? Advocate for poverty reduction, education, health equity, labor market access and intergenerational justice where you live. Those are the metrics used for the EU Social Justice Index that researchers linked to each country's life satisfaction.

READ MORE: People of color face significant barriers to mental health services

Researchers studying the science of well-being agree that human connection is key. But in a pandemic, what really works?

Your voice, it turns out. Phone calls and video calls create stronger social bonds than email or text, found researcher Amit Kumar, an assistant professor of marketing at University of Texas at Austin's McCombs School of Business, in a recent study published by the Journal of Experimental Psychology.

Worried that calling will be awkward? You're not the only one to think so.

Many study participants overestimated the awkwardness of voice calls, while underestimating the benefits. That may be one reason some avoid calling altogether, a misunderstanding with real consequences for well-being.

Do it: Instead of tapping out a text or email, choose a video or voice call instead.

Are kids naturally cooperative? Children showed more self-control when working toward a collective goal than an individual one, according to a 2020 study published by the journal Psychological Science.

For the study, hundreds of small children tested their will by trying not to eat a cookie. If they could wait it out for long enough, they'd get a second cookie as a reward.

Here's the twist: In some versions of the test, the kids worked in teams. Together, they did better, earning more cookies for all.

Do it: This study targets kids, but adults can benefit from cooperation, too. If you have a 2021 goal or resolution, consider asking a friend to join you; as a team, you might find even greater success.

There is more than one way to live well. Typically, researchers focus on two important metrics for evaluating the good life. One is pleasure; the other is all about deeper meaning.

In a 2020 paper, however, Shigehiro Oishi, a professor of psychology at the University of Virginia, proposed a new dimension for understanding a life well lived: psychological richness. That term underscores the value of variety, interest and novelty.

A life of psychological richness is full of diverse experiences and discovery, offering challenges that stimulate your mind. It might not always be easy but it will be interesting.

Do it: Seek out experiences likely to shift your perspective. Try taking up a new hobby, for example, or exposing yourself to a foreign culture.

Saying "thank you" can make the world a better place. How? It's what researchers call the witnessing effect, where seeing a behavior can change the actions of onlookers.

After watching expressions of gratitude, participants in one study were more likely to be helpful, open and friendly. Kindness can create a similar outcome, found another study.

Do it: If you need some motivation to be kind or to say "thank you" more remember that the benefits don't stop with you. You have the power to change your community's behavior, too.

Research shows that extroverts have it pretty good. The personality trait, which tends to go along with highly social behavior, is correlated with increased happiness.

But that doesn't mean the benefits of extroversion are off-limits for introverts. Just acting like an extrovert for a week correlated with increased well-being for participants in a study published by neuropsychologist Seth Margolis, an assistant professor of psychiatry and human behavior at Brown University.

Do it: Stage your own experiment. Even if you're a lifelong introvert, spend one week channeling extroverted behavior by seeking out (pandemic-safe) social situations and increasing interaction with others.

How can you convince people to wear a mask, practice social distancing and take other measures to reduce the spread of Covid-19? It's not public shaming.

In fact, people are more likely to comply with messages emphasizing the importance of caring for others, found Jillian Jordan, assistant professor of business administration at Harvard Univeristy. That finding echoes another study from the University of Zurich, which argued that "a large majority of people are very reluctant to put others at risk for their personal benefit."

That's great news as the world continues to cope with the ongoing pandemic.

Do it: If someone in your life isn't doing their part to reduce the spread of Covid-19, don't attempt to shame them into changing their ways. Try to appeal to their altruism.

What's the root of inequality? How you answer the question might influence your behavior.

If you believe that widespread poverty is the result of life circumstances rather than laziness or personality you're more likely to support egalitarian policies, found one 2020 study.

Not only that, both beliefs and behavior can change. The same researchers went on to show that inviting study participants to reflect on the root causes of poverty made them more likely to donate money to a campaign supporting a higher minimum wage.

Do it: Take a pause next time you find yourself judging someone facing difficult circumstances. You might be making some incorrect assumptions about the underlying reasons for the situation they're facing.

Nothings banishes stereotypes like real-world experience, found a 2020 study that compared regions' ethnic diversity with the prevalence of stereotypes. The authors call it a "diversity paradox."

It turns out that when we cross racial, cultural and ethnic lines more often, we notice how similar we are to those around us, instead of focusing on the small differences.

Do it: You could move to an ethnically diverse place the study authors used South Africa and Hawaii as prime examples.

Short of that? Seek out situations where you'll rub shoulders with people who are different from you, with a focus on reducing your own tendency to use stereotypes.

Jen Rose Smith is a writer based in Vermont. Find her work at jenrosesmith.com, or follow her on Twitter @jenrosesmithvt.

Read the rest here:
10 things we learned in 2020 about living the good life - KCTV Kansas City

Pentagram’s holiday card has some of the most poignant advice for 2021 – Fast Company

Most holiday cards are festive celebrations of the season. You know the kind: sparkly, heartwarming, may accompany a fruitcake.Design agency Pentagram took this years card one step further, with a list of items that can double as New Years resolutions.

[Image: courtesy Pentagram]The card is based on celebrated architect Michael Sorkins 250 Things an Architect Should Know from his 2018 book, What Goes Up. Sorkin died earlier this year from COVID-19 complications and was remembered as a fierce champion of architecture and urban design as a medium for social justice. While his list was targeted toward architects, much of the advice functions as a guiding philosophy for just about anyone.

Pentagram partner Michael Bierut and associate partner Britt Cobb designed the card, which features all 250 items. (Card is also a bit of a misnomerits actually a 24-page booklet.) Some of the entries are also paired with red-and-black line illustrations by illustrator Chris DeLorenzo.

Pentagram has been sending out holiday booklets since 1974, just two years after the international design firm was founded. This years version went out to about 3,000 recipients, according to Bierut. The cards, which have a different creative twist each year, are a case study in designing corporate communications that are actually good.(Last years card, designed by partner Yuri Suzuki, had a clever interactive component.)

[Image: courtesy Pentagram]The newest card pays tribute to Sorkin, who advocated a holistic perspective and challenged people to design, create, and live with the world in mind. He was a theorist who was extremely practical, says Bierut, who served with Sorkin on the board of the Architectural League of New York for about 20 years. What always came through was his ability to act in the world not as an architect, nor as a critic, but as a human being.

[Image: courtesy Pentagram]The 250 items on the listeverything Sorkin believed an architect should knowcan be read as individual pieces of advice, but some entries show additional nuance by unfurling into the next, like lines in a stanza. Take one such group Bierut calls out:

39. What the client wants.40. What the client thinks it wants.41. What the client needs.42. What the client can afford.43. What the planet can afford.

Its a a lovely bit of rhetorical sleight of hand in a piece thats full of them, he says.

[Image: courtesy Pentagram]The universality of Sorkins perspective is especially striking. Sure, there are things you need to know as a designer. But most of them are things that would simply make you a better person, Bierut says of the list. It does include straight design tips (38. The color wheel), but it also pushes the reader to think more broadly about human behavior, social policies, and philosophical questions (247. The depths of desire). The list encouragesand inspirespeople to consider the context and implications of their work: Does it make the world more sustainable? More just?

Much like Sorkins outlook, the real lesson for Bierut was broad in scope: that being relentlessly curious and open to new experiences makes you a better designer and a better human being.

See the full list here.

See original here:
Pentagram's holiday card has some of the most poignant advice for 2021 - Fast Company

Dr. John Torres: Heres how to make Olympics happen safely in 2021 – WETM – MyTwinTiers.com

COLUMBUS (WCMH) Tokyo 2020 in 2021? Thats still the plan from the International Olympic Committee. But there is still plenty to figure out, including whether it is safe enough to hold the Olympics as the world continues to go through the coronavirus pandemic.

The number of positive cases are growing each day. As of October, there have been more than 40 million cases globally and more than 8.2 million cases in the United States, according to Johns Hopkins University. And more than 1.1 million people have died globally.

NBC News Senior Medical Correspondent Dr. John Torres has been following the progress of the coronavirus from the beginning. As most medical experts, he is worried about the rise in cases weve seen both nationally and internationally.

Globally, weve taken a bit of a step back in the fight against coronavirus. Things looked like they were doing fairly well in certain parts of the world, especially in Europe, but once things started re-opening, once people started getting out and getting together again, those cases started to creep up and started to surge up, even right here in the United States, Torres said.

As we start to get into our cold weather months, youre going to see more cases of coronavirus. The difference is we have a better understanding of how to handle it and a better understanding of how to shut down things and what we need to shut down to keep it under control.

Much of the focus as it pertains to the coronavirus is the progression of a vaccine. Some countries have already started to distribute their vaccines while in the United States, the timeline is not as clear.

So what theyre talking about is probably having a vaccine here in the U.S. available sometime in the beginning of the year, maybe springtime, but remember, there are going to be phased-in distributions because you cant give 330 million people in the U.S. vaccines all on day one, Torres said.

Now switching to globally, theyre a little further ahead in the vaccine as far as getting it distributed and getting vaccines to people. Russia and China are doing that already. But using our safety measures, we would never do that at this stage. And so it seems they are ahead of where we are, were not exactly sure how safe and effective that vaccine they are using is and whether that is something we would use here at this point.

IOC chairman Thomas Bach has signaled that the Olympics could be staged successfully without a vaccine, pointing to other sporting events like the Tour de France that finished its competition during the pandemic. Dr. Torres agrees with Bach, pointing to other prevention measures to help contain any potential spread.

Its possible they could do the Olympics without a vaccine, but theyre going to have to be very, very careful and very stringent with athletes and the officials because one case there could ruin the whole Olympics for many, many athletes and officials. And it could essentially cancel the Olympics, said Torres.

The vaccine is not going to end the pandemic. Its one tool we have to ending the pandemic. And using that along with face masks, social distancing, hand-washing, those tools we know work are going to be the key to getting this under control so without the vaccine, you can still get it under control but you have to monitor that human behavior.

With more than 8 months until the rescheduled opening ceremony in Tokyo on July 23, 2021, optimism remains high among athletes that they will get a chance to compete. Same goes for the IOC and officials in Japan, who have said repeatedly that they will not postpone the Games again.

Torres thinks the example set by American sports leagues and those around the world also provide the IOC plenty of information they can use on what works and doesnt work as far as staging the Games. He also believes everything should be on the table, from mandatory testing, mask wearing, restricting fans and creating a bubble of sorts to keep everyone safe.

Im very confident that well be able to see the Olympics in July and August 2021 for a couple reasons. One, because theyve postponed them a year and weve learned a lot about the virus and how to handle it, said Torres. And two, its one of those symbols thats going to show us that yes, were getting through, were getting back to at least a new normal and its something that we can all look forward to and give the whole world confidence that together, we will get through the pandemic.

See the original post here:
Dr. John Torres: Heres how to make Olympics happen safely in 2021 - WETM - MyTwinTiers.com